Antimicrobial Agents and Chemotherapy, October 2004, p . 3940-3943, Vol . 48, No . 10

In 1998, we observed a significant rate of failure of CQ monotherapy in The Gambia and showed that this was linked to mutations in two genes of Plasmodium falciparum: pfcrt and pfmdr1 (8) . The combination CQ-AS was evaluated in 2000 in the hope that satisfactory efficacy would be exhibited, leaving sulfadoxine-pyrimethamine and other affordable antimalarial drugs in reserve as treatments for recrudescent infections (9) . Both the efficacy of treatment with this combination and its ability to decrease the rate of transmission of CQ-resistant parasites from treated individuals have been reported previously (2, 9) .

Parasitological and entomological data suggest that CQ-treated patients with persisting drug-resistant parasites carry higher densities of mature gametocytes and are more infectious to mosquitoes than successfully treated patients (2, 4, 6, 7) . However, these experiments were carried out without molecular confirmation that the resistance-associated alleles pfcrt and pfmdr1 were present in infections with higher rates of transmission success . In this study we present new evidence that, under CQ monotherapy, genetically resistant parasites are significantly more transmissible to Anopheles mosquitoes than sensitive parasites . Under combination therapy with CQ and AS, however, enhancement of transmission of resistant parasites does not occur .

Study subjects. The clinical treatment trial held in Farafenni, The Gambia, in 2000 and the associated experiments of feeding through a membrane that provided the samples for this study are described in detail elsewhere (2, 8) . Briefly, 536 children with mild malaria were recruited and treated either with CQ alone (n = 136; 25 mg of oral CQ base [Alkaloida Ltd., Tiszavasvári, Hungary] per kg of body weight over 3 days) or with a combination of CQ and three doses of AS (n = 400; 4 mg of AS [Guilin Pharmaceutical Works, supplied by Sanofi, Paris, France] per kg with each dose of CQ) . Eligible children were aged 1 to 9 years and had a body weight >5 kg, a history of fever, and asexual parasitemia at levels of >500 parasites/µl of blood . Exclusion criteria included anemia (packed cell volume [PCV], <20%), any other signs or symptoms of severe malaria, an inability to take drugs orally, treatment with any antimalarial within the past 2 weeks, and any evidence of chronic disease or other acute infection . Field assistants visited each child at home on postrecruitment days 3, 14, and 28 . On each occasion a finger-prick blood sample was taken and used to make a thick film for microscopy and a filter paper blood spot for DNA extraction . On day 7, the patients were brought to the Medical Research Council laboratory in Farafenni, where samples for thick blood film and PCV estimation were obtained .

Mosquito infections. Blood from children who were gametocytemic on the day 7 follow-up visit (limit of detection, 5 gametocytes/µl) and who had a PCV >20% was selected for the membrane feeding experiments . Venous blood samples (2 to 3 ml) were taken from consenting gametocyte carriers and fed through a membrane to female Anopheles gambiae mosquitoes in cages, with approximately 50 mosquitoes per cage, as described previously (2, 10) . If the number of gametocyte-positive patients was greater than the number of cages of mosquitoes available for feeding on a particular day, consenting gametocyte carriers were selected in the order in which the finger-prick blood samples were obtained . The carriers were selected independently of the treatment group . The midguts of the blood-fed mosquitoes were dissected 7 to 8 days after they were fed, and the number of P . falciparum oocysts was counted and used as the primary transmission end point .

Parasite genotyping. DNA was extracted from the blood spots on filter paper obtained on day 0 and from pellets of venous blood obtained on day 7 . Oocyst DNA was obtained from the pooled midguts of oocyst-positive mosquitoes from a single cage of fed mosquitoes . Two mutations in key parasite genes, a threonine (T) encoded by codon 76 of pfcrt and a tyrosine (Y) encoded by codon 86 of pfmdr1, are strongly associated with CQ treatment failure in this population (8) . These amino acid substitutions result from single nucleotide substitutions that were detected by a sequence-specific oligonucleotide probing assay, as described previously (1, 8) . Infections harboring mixtures of CQ-sensitive and CQ-resistant parasites were scored as resistant to reflect the expected phenotype of the infection .

Data analysis. To compare midgut oocyst burdens between groups of mosquitoes fed through a membrane, the ratio of the arithmetic means was fitted to the negative binomial distribution, with compensation for within-patient clustering, as described previously (2) . Adjustment for confounding between the pfcrt and pfmdr1 loci was made . The difference between two proportions was tested by using the ² statistic . Gametocyte density was also fitted to the negative binomial for comparison of (unadjusted) means between groups . Directional selection within hosts was evaluated by McNemar's test .

 
Among patients treated with CQ monotherapy, the day 7 gametocytes from those carrying pfcrt-76T parasites prior to treatment produced 38-fold more midgut oocysts than did those from patients carrying the wild-type allele, pfcrt-76K . Similarly, mosquitoes fed on day 7 gametocytes from CQ-treated children carrying pfmdr1-86Y parasites prior to treatment carried approximately 14-fold more midgut oocysts than mosquitoes fed on blood from patients carrying the wild-type allele (Table 1) . This confirms that the pfmdr1-86 genotype has an incremental effect on parasite transmission separate from that of pfcrt-76 . Therefore, as predicted by parasitological and entomological data, treatment of human hosts with CQ monotherapy imparts to the parasites carrying CQ resistance genes a considerable transmission advantage compared with that for sensitive parasites .

What effect does combination therapy have on this transmission benefit? Among children receiving the CQ-AS combination, the parasites carrying pfcrt-76T enjoyed no transmission advantage (Table 1); the ratio of the adjusted mean oocyst burdens was 2.58% of the ratio observed under CQ monotherapy (95% confidence interval [CI], 0.6 to 11.8%; P < 0.001) . Under CQ-AS therapy, the pfmdr1-86Y genotype was associated with a statistically significant fourfold lower oocyst burden . There is thus a transmission deficit among those carrying pfmdr1-86Y rather than pfmdr1-86N under CQ-AS treatment . The adjusted mean ratio for these children was 1.82% of the ratio for those receiving CQ (95% CI, 0.16 to 21%; P = 0.001) . Therefore, the addition of AS to CQ monotherapy nullifies the greater transmissibility of CQ-resistant infections, supporting the notion that artemisinin-based antimalarial combination therapy can reduce the transmission of drug-resistant malaria parasites from treated patients (5, 8, 12) .

In order to understand the mechanism of enhanced transmission, we identified changes in the pfcrt-76 or pfmdr1-86 genotype occurring between samples obtained on day 0 and those obtained on day 7 posttreatment from all gametocyte donors, irrespective of whether the patient presented with gametocytemia (n = 69) . Changes in the pfcrt-76 genotype were noted in eight infections, seven of which went from the wild type to the resistant genotype (P = 0.0339), suggesting that after 7 days of drug pressure, the selection of gametocytes carrying pfcrt-76T was occurring within the human host . Evidence of this directional selection was also apparent when we compared pretreatment parasites with midgut oocysts from patients with infections that were successfully transmitted to mosquitoes; five of five changes were from pfcrt-76K to pfcrt-76T (Table 2) (P = 0.025) . Both of the changes observed between the parasite genotype on day 7 posttreatment and the genotype of the resulting oocysts were also from pfcrt-K to pfcrt-76T (Table 2) (P = 0.157), suggesting that additional directional selection may occur in the mosquito midgut . However, a larger sample would be required to test this . CQ treatment pressure contributed to selection in both treatment groups (data not shown) . No evidence of directional selection for pfmdr1-86N/Y was seen at any stage, as genotype changes were observed in both directions (Table 2) . Our interpretation of these findings is that drug selection for pfcrt-76T, but not pfmdr1-86Y, does occur among gametocytes in treated patients and that the CQ resistance genotype of the transmitted parasites in infected mosquitoes largely reflects the genotypes of the circulating gametocytes from which they are descended .

 
The enhanced transmission of CQ-resistant parasites that we have observed may be a direct effect of higher gametocyte numbers in infections caused by resistant parasites (2, 4, 6-8, 10) . We therefore examined the relationship between the pretreatment resistance genotype and the gametocyte density on day 7 posttreatment in both drug treatment groups (Table 3) . As predicted, those children in the CQ treatment group harboring parasites with either resistance allele prior to treatment carried significantly higher gametocyte densities on day 7 posttreatment . This was not seen in the CQ-AS treatment group .

 
Thus, artemisinin-based combination therapy for acute uncomplicated falciparum malaria in African children can overcome the transmission advantage of parasites genetically resistant to the primary drug . Under CQ monotherapy, resistant parasites enjoyed a 14- to 38-fold higher intensity of transmission to mosquitoes, which was ablated in the combination group . Exposure to AS rendered parasites carrying the pfmdr1-86Y allele less infectious than wild-type parasites, consistent with predictions from in vitro studies that pfmdr1 mutants are more sensitive to artemisinins than parasites with wild-type pfmdr1 (3) . This provides an explanation for the apparent lack of directional selection for the pfmdr1-86Y allele among the gametocyte donors (Table 2) .

Gametocytes arising from resistant parasites had a selective advantage in the CQ-treated host, even if their asexual progenitors were present at levels below the PCR detection threshold at the time of treatment . This is why in a small number of infections, apparently wild-type parasites gave rise to resistant gametocytes at day 7 . We cannot say whether the gametes (and ookinetes) arising from these gametocytes enjoyed a further selective advantage in the mosquito host . We can say that a key parameter of the transmission success of resistant parasites is the production of greater numbers of mature circulating gametocytes, which are present over an extended period of time after treatment (2, 4, 6, 7, 10) . Our findings are that CQ-AS reduces the infectivity of resistant parasites at day 7 . However, children in the CQ-AS treatment group frequently became gametocyte positive in the third and fourth weeks after treatment and carried gametocytes at relatively high densities (2), which shows that this particular combination would not provide a sustainable long-term benefit in reducing the spread of drug-resistant parasites . Other AS combinations tested with the same population, such as sulfadoxine-pyrimethamine plus AS or co-artemether (10, 11), give more sustained reductions in the levels of gametocyte carriage, as the level of resistance to the accompanying drug(s) remains low .

This work supports a major rationale for combination theory: that its implementation can reduce the spread of drug-resistant parasites in areas of endemicity . Thus, the concerted use of fully effective artemisinin-containing antimalarial combinations in sub-Saharan Africa should counteract the enhanced transmission of drug-resistant parasites . Our study also illustrates the importance of analysis of the molecular genetics of the parasite in both the human and the mosquito hosts for evaluation of the effectiveness of combination therapy interventions . Such studies are needed to inform the critical choice as to which combination should be deployed in a particular setting .

We thank Cally Roper for helpful comments on the manuscript and Brian Greenwood for comments on the manuscript, support, and encouragement . This work would have been impossible without the continuing cooperation of the people of Farafenni .

R.L.H . and C.J.S . made equivalent contributions to the work .

Present address: Community Health, Aga Khan Health Services, Secrétariat de Son Altesse l’Aga Khan Aiglemont, 60270 Gouvieux, France .

Present address: Community Health, Aga Khan Health Services, Secrétariat de Son Altesse l’Aga Khan Aiglemont, 60270 Gouvieux, France .

Present address: IRIS Research Center, Chiron Vaccines, 53100 Siena, Italy .

1. Alloueche, A., H . Silveira, D . J . Conway, K . Bojang, T . Doherty, J . Cohen, M . Pinder, and B . M . Greenwood. 2000 . High-throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein . Mol . Biochem . Parasitol . 106:273-282.
2. Drakeley, C . J., M . Jawara, G . A . T . Targett, G . Walraven, U . Obisike, R . Coleman, M . Pinder, and C . J . Sutherland. 2004 . Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes . Trop . Med . Int . Health 9:1-9.
3. Duraisingh, M . T., L . V . von Seidlein, A . Jepson, P . Jones, I . Sambou, M . Pinder, and D . C . Warhurst. 2000 . Linkage disequilibrium between two chromosomally distinct loci associated with increased resistance to chloroquine in Plasmodium falciparum. Parasitology 121:1-7.
4. Handunnetti, S . M., D . M . Gunewardena, P . P . S . L . Pathirana, K . Ekanayake, S . Weersinghe, and K . N . Mendis. 1996 . Features of recrudescent chloroquine-resistant Plasmodium falciparum infections confer a survival advantage on parasites and have implications for disease control . Trans . R . Soc . Trop . Med . Hyg . 90:563-567.
5. Price, R . N., F . Nosten, C . Luxemburger, F . O . ter Kuile, L . Paiphun, T . Chongsuphajaisiddhi, and N . J . White. 1996 . Effects of artemisinin derivatives on malaria transmissibility . Lancet 347:1654-1658.
6. Robert, V., H . P . Awono-Ambene, J . Y . Le Hesran, and J . F . Trape. 2000 . Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine . Am . J . Trop . Med . Hyg . 62:210-216.
7. Sowunmi, A., and B . A . Fateye. 2003 . Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs . Trop . Med . Int . Health 8:783-792.
8. Sutherland, C . J., A . Alloueche, J . Curtis, C . J . Drakeley, R . Ord, M . Duraisingh, B . M . Greenwood, M . Pinder, D . Warhurst, and G . A . T . Targett. 2002 . Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes . Am . J . Trop . Med . Hyg . 67:578-585.
9. Sutherland, C . J., C . J . Drakeley, U . Obisike, R . Coleman, M . Jawara, G . A . T . Targett, P . Milligan, M . Pinder, and G . Walraven. 2003 . The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure . Am . J . Trop . Med . Hyg . 69:19-25.
10. Targett, G . A . T., C . Drakeley, M . Jawara, L . von Seidlein, R . Coleman, J . Deen, M . Pinder, T . Doherty, C . Sutherland, G . Walraven, and P . Milligan. 2001 . Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J . Infect . Dis . 183:1254-1259.
11. von Seidlein, L., K . Bojang, P . Jones, S . Jaffar, M . Pinder, S . Obaro, T . Doherty, M . Haywood, G . Snounou, B . Gemperli, I . Gathmann, C . Royce, K . McAdam, and B . Greenwood. 1998 . A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children . Am . J . Trop . Med . Hyg . 58:638-644.
12. White, N . J., F . Nosten, S . Looareesuwan, W . M . Watkins, K . Marsh, R . W . Snow, G . Kokwaro, J . Ouma, T . T . Hien, M . E . Molyneux, T . E . Taylor, C . I . Newbold, T . K . Ruebush II, M . Danis, B . M . Greenwood, R . M . Anderson, and P . Olliaro. 1999 . Averting a malaria disaster . Lancet 353:1965-1967.
13. World Health Organization. 2003 . Africa malaria report . World Health Organization, Geneva, Switzerland.

Free Online Full-text Article

What Is Yeast?, What Is MIC?, What Is Protein?, What Is Prokaryote?, What is Food Microbiology?, r, Bacteria, i, Microbiology, i, Microbe, o, Bacteriology, s, Microorganisms, o, Escherichia coli, s, Bacillus, s, Staphylococcus, i, Enterococci, i, Salmonella typhimurium, a, Neisseria, a, Bacteria, r, S. cerevisiae, r, Salmonella, s, S. cerevisiae, e, Staphylococcus aureus, i, Bacteria, a, Campylobacter, n, Escherichia coli, r, Bacillus, r, Antibiotics, n, Cholera, i, Erythromycin, r, S. cerevisiae, n, Serratia, o, Rhizobacterium




 

© 2005 Transgalactic Ltd (manufacturer of Bioscreen C software) | Privacy Statement | P.O. Box 1393, 00101 Helsinki, Finland, phone: +358 9 85172920, fax: +358 9 8749481, e-mail: microbiology@bionewsonline.com
 

Last modified: May 25, 2005